key: cord-1038071-8is04ai9
authors: Chiodini, Paolo; Arenare, Laura; Piccirillo, Maria Carmela; Perrone, Francesco; Gallo, Ciro
title: A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan
date: 2020-10-07
journal: Contemp Clin Trials Commun
DOI: 10.1016/j.conctc.2020.100665
sha: c5ad3dcba3f39d885de5204d80dddf34e75845c0
doc_id: 1038071
cord_uid: 8is04ai9

BACKGROUND: Tocilizumab, an IL-6 receptor antagonist, was suggested as a possible treatment of severe or critical COVID-19 pneumonia in a small Chinese study. The TOCIVID-19 trial evaluates efficacy and tolerability of tocilizumab in the treatment of patients with severe or critical COVID-19 pneumonia. METHODS: TOCIVID-19 is an academic multicenter, single-arm, open-label, phase 2 study. All the patients are being offered a single shot of 8 mg/kg of Tocilizumab (up to a maximum of 800 mg), with an eventual second administration at the discretion of the Investigator. A companion prospective cohort, added to corroborate internal validity, includes either patients not eligible for phase 2 or subjects eligible for phase 2 but exceeding the planned sample size. 14- and 30-days lethality rates are the two co-primary endpoints in the intention-to-treat (ITT) population. Secondary objectives are to evaluate mortality and clinical improvement in the modified-ITT population of subjects who received the drug. Details of the methodological and statistical approaches are reported here reflecting the amendments impelled by the continuously increasing knowledge on COVID-19 progression and challenges in data collection. CONCLUSION: This paper provides details of planned statistical analyses for TOCIVID19 trial to reduce the risk of reporting bias and increase validity of the study findings. TOCIVID-19 trial is registered in the EudraCT database with number 2020-001110-38 and in clinicaltrials.gov with ID NCT04317092.

phase 2 or subjects eligible for phase 2 but exceeding the planned sample size. 14-and 30-days 23 lethality rates are the two co-primary endpoints in the intention-to-treat (ITT) population. 24 Secondary objectives are to evaluate mortality and clinical improvement in the modified-ITT 25 population of subjects who received the drug. Details of the methodological and statistical 26 approaches are reported here reflecting the amendments impelled by the continuously increasing 27 knowledge on COVID-19 progression and challenges in data collection. 28 Conclusion. This paper provides details of planned statistical analyses for TOCIVID19 trial to 29 reduce the risk of reporting bias and increase validity of the study findings. 30 TOCIVID-19 trial is registered in the EudraCT database with number 2020-001110-38 and in 31 clinicaltrials.gov with ID NCT04317092.

Background and rationale 37 This multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients 38 with COVID-19 pneumonia (TOCIVID-19) has been realized in the context of the COVID-19 39 epidemics in Italy. Such epidemic has led to a rapidly increasing number of cases of interstitial 40 pneumonia with a high case-fatality ratio and a tremendous burden on Italian intensive and sub- 41 intensive care units. The number of deaths associated with COVID-19 in Italy is high , and is mainly 42 concentrated in a few Regions (Lombardia, Piemonte, Emilia-Romagna, Veneto). [1, 2] 43 Tocilizumab, an IL-6 receptor antagonist, is an anti-inflammatory drug used in rheumatology for 44 the treatment of some forms of arthritis and in oncology to fight the 'cytokine storm' subsequent 45 to immunotherapy. It was suggested as a possible treatment of severe or critical COVID-19 46 pneumonia by Chinese researchers [3] in a cohort of 21 patients whose clinical variables improved 47 dramatically. Then a randomized trial comparing tocilizumab versus control started in China 48 evaluating about 190 patients [4] ; as far as we know the trial is still ongoing. After the initiation of 49 the present study two other randomized phase 3 trials have been launched by the University of 50 Oxford (EudraCT 2020-001113-21) and by the drug manufacturer (NCT04320615). 51 Notwithstanding the previous limited information, tocilizumab was steadily used off-label in Italy 52 to treat severe or critical COVID-19 pneumonia, and anecdotical initial positive results reported by 53 physicians gave rise to a massive media campaign for a generalized use of drug. Thus, the main 54 concern was to provide more accurate and methodologically sound information on the efficacy of 55 tocilizumab. The TOCIVID-19 trial is a single-arm open label phase 2 study designed to assess the efficacy of 59 tocilizumab in reducing mortality of patients with severe or critical COVID-19 pneumonia. The aim 60 of this Statistical Analysis Plan (SAP) is to report in detail the methodological and statistical 61 approaches to the analysis of the data whilst still blind to any analyses of efficacy study outcomes. 62 This SAP is produced at the end of April 2020, and any deviations will be documented in the The single-arm design was prompted by social needs and feasibility reasons. On one hand, 75 although the rationale behind the use of tocilizumab is clinically plausible, previous Chinese Thus, this study design represents the effort to strike a balance between the clinicians' demand on 82 one side and the scientific need to have the most accurate information by governing the data 83 collection on a formalized basis. 84 Because of the unprecedented situation of COVID-19 pandemic, inadequate information was 85 available when the trial was planned, and this SAP reflects the subsequent amendments impelled 86 by the continuously increasing knowledge. 87 The planned number of patients of phase 2 population was completed in less than 24 hours, from 88 March 19 to March 20, 2020. The core phase 2 trial was complemented by a further cohort of 89 patients treated with Tocilizumab at the same doses, with a prospective and a retrospective 90 component. The prospective cohort was defined as treated patients not enrolled in the phase 2 91 cohort, but prospectively registered before receiving Tocilizumab. The prospective cohort includes r the findings of this validation cohort would corroborate the internal validity of the study main 105 results . 106 This SAP only refers to the phase 2 and validation cohorts. The remaining patients from the 107 prospective and retrospective cohorts will be investigated in separate analyses. As of March 15, 2020, when only preliminary data were available, 330 patients were planned 152 assuming a 15% 1-month lethality rate as H 0 , an alternative hypothesis (H 1 ) equal to 7.5% (i.e. 153 halving the risk of death) with a very high power 0.99 and two-tailed alpha level equal to 0.05. 154 As more Italian data were available, it was evident that initial null hypothesis was seriously 155 underestimated and should be refined. 156 A main concern was the accessibility of data referring to patients hospitalized with severe or 157 critical COVID 19 pneumonia. As of April 12, 2020, from data of Minister of Health we calculated For time-to-event analyses, estimates of cumulative probabilities of the event will be provided 309 with 95% CIs. Cumulative probabilities of event will be estimated by using 1 minus Kaplan-Meier 310 estimator or by using cumulative incidence estimator in the presence of other competing events 311 [11] . Median time to event and interquartile range will be calculated for subjects with event. In 312 the absence of additional vital status data, patient discharged earlier than 30 days to home or to 313 low-intensity care setting will be considered alive at the end-date of 30 days. Dependency on 314 waiting time to treatment will be investigated by non-parametric hazard curves of death in 315 predefined subgroups of waiting times according to 'clock back' scale [12] . Time-to-event analysis 316 will be performed on ITT and mITT populations. Information on time-to-event analyses will be 317 described also for baseline subgroups defined by demographic and clinical variables. A sensitivity 318 analysis will be performed by considering patients discharged earlier than 30 days to home or low-319 intensity care settings as competing events and using cumulative incidence estimator. 320 J o u r n a l P r e -p r o o f 321 is entered as a time-dependent covariate, to properly account for immortal-time bias [13] . 322 Proportionality assumption will be tested by Schoenfeld residuals. 323 For time to death, all patients will be included in the analysis and patient discharged earlier than 324 30 days to home or to low-intensity care setting will be considered alive at the end-date of 30 325 days. 326 For time to invasive mechanical ventilation, patients with invasive mechanical ventilation within 327 24 hours from registration date will be excluded from the analysis and death will be considered as 328 competitive event. Patient discharged earlier than 30 days to home or to low-intensity care setting 329 will be considered without ventilation at the end-date of 30 days. 330 For time to definitive extubation, patients without invasive mechanical ventilation within 24 hours 331 from registration date will be excluded from the analysis and death will be considered as 332 competitive event. Patient discharge to home or to low-intensity care setting will be considered as 333 event when data of definitive extubation is missing. 334 For time to independence from non-invasive mechanical ventilation, only patients with non-335 invasive mechanical ventilation within 24 hours from registration date will be included in the 336 analysis and death will be considered as competitive event. Patient discharge will be considered as 337 event if data of independence from non-invasive mechanical ventilation is missing. 338 For time to independence from oxygen therapy, all patients will be included in the analysis (due to 339 eligibility criteria) and death will be considered as competitive event. Patient discharge to home or 340 to low-intensity care (in both cases with independence from oxygen therapy) will be considered as 341 event when data of independence from oxygen therapy is missing. Hence, in agreement with IDMC, it was decided to remove from any analysis all patients recruited 385 from uncooperative centers providing less than 25% of information on baseline characteristics and 386 treatment administration. We had no information on reasons why the uncooperative centers 387 provided so few data, but we cannot exclude that it was related to baseline (or outcome) patient's 388 characteristics. Thus, rather than using only patients for which information was available, we 389 assumed that information was unreliable for all subjects in that center, and, with the agreement of the IDMC, we decided to remove the whole center from all analyses. It was agreed that a 391 boundary of 25% was low enough to still permit the participation of a sufficient number of 392 patients. 393 All other patients are included in primary ITT analyses and frequency distributions of missing data 394 will be reported for all variables assessed in the trial. 

What other countries can learn from Italy during the 426 COVID-19 Pandemic

Excess mortality from COVID-19: a commentary on the Italian 428 experience

ChinaXiv: 202003.00026v1

A multicenter, randomized controlled trial for the efficacy and safety of 433 tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)

Guidelines for the content of statistical analysis plans 436 in clinical trials

Survival of 441 hospitalized COVID-19 patients in Northern Italy: a population-based cohort study by the 442 ITA-COVID19 Network

International Council on Harmonization of Technical Requirements for Registration of 444 Pharmaceuticals for Human Use

CONSORT 2010 statement: updated 448 guidelines for reporting parallel group randomised trials

Non-parametric inference for cumulative incidence functions in competing risks 450 studies

Survival probabilities with time-dependent 452 treatment indicator: quantities and non-parametric estimators

Simulation shows undesirable 455 results for competing risks analysis with time-dependent covariates for clinical outcomes

Laura Arenare and Ciro Gallo have no competing interests. Francesco Perrone and

Maria Carmela Piccirillo coordinate three academic clinical trials in oncology